Disease Progression, Adherence, and Response to Protease Inhibitor Therapy for HIV Infection in an Urban Veterans Affairs Medical Center
- 1 December 1999
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 22 (4) , 358
- https://doi.org/10.1097/00042560-199912010-00006
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 InfectionJAMA, 1998
- A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)‐1 Protease, to Treat HIV InfectionThe Journal of Infectious Diseases, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992
- A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle MaturationScience, 1990
- Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analoguesNature, 1990
- Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.Proceedings of the National Academy of Sciences, 1989
- Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.Proceedings of the National Academy of Sciences, 1989
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988